DaVita Launches Initiatives to Enhance Dialysis Outcomes for Kidney Disease Patients
- DaVita launches two programs to enhance middle-molecule removal understanding in kidney failure patients.
- The MODEL initiative evaluates survival rates using medium cut-off dialyzers for improved health outcomes.
- DaVita aims to set new dialysis care standards through research, enhancing patient health and quality of life.
DaVita Launches Groundbreaking Initiatives to Improve Dialysis Outcomes
DaVita Inc. initiates two significant programs aimed at enhancing the understanding of middle-molecule removal in patients suffering from kidney failure. This development comes in response to research that highlights the dangers of larger waste particles accumulating in the bloodstream, which can lead to heightened inflammation and a compromised immune system, negatively affecting patient outcomes. While previous studies conducted internationally have examined the advantages of middle-molecule removal, the lack of U.S.-based evidence has motivated DaVita to take action. Over the next two years, the company plans to involve around 9,000 adults living with end-stage kidney disease (ESKD) in these initiatives.
The first initiative, MODEL, focuses on evaluating the survival rates of patients utilizing medium cut-off dialyzers as part of their treatment regimen. This quality improvement initiative represents a critical step toward understanding how these dialyzers can effectively remove middle molecules, potentially leading to better health outcomes. The second initiative, the MEMOIRS survey, is a prospective cohort study that seeks to compare patient-reported outcomes between individuals treated with medium cut-off and those using high-flux dialyzers. Francesca Tentori, MD, emphasizes DaVita’s dedication to advancing treatment for kidney failure through innovative scientific research, which is expected to yield insights that will guide nephrologists in making optimal treatment decisions.
Chief Medical Officer Jeff Giullian, MD, notes that these initiatives may represent a pivotal moment in the evolution of dialysis treatment, akin to the introduction of hemodialysis in 1945. By generating robust data, DaVita aims to set new standards of care that enhance patient outcomes within the U.S. dialysis landscape. The findings from these studies are anticipated to inform best practices in nephrology, promoting a renewed focus on treatment innovations that can lead to improved patient health and quality of life.
In addition to these initiatives, DaVita encourages stakeholders to explore further information on their website, DaVita.com/TreatmentInnovation. The company’s commitment to advancing kidney health through scientific research and innovation solidifies its role as a leader in the dialysis field, aiming to improve the lives of those affected by kidney disease.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

